Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 273 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 9, 41, 26 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively.Ebolavirus Infections (Ebola Hemorrhagic Fever).

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ebolavirus Infections (Ebola Hemorrhagic Fever) Overview 11
Therapeutics Development 12
Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview 12
Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Comparative Analysis 13
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics under Development by Companies 14
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics under Investigation by Universities/Institutes 18
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Products under Development by Companies 23
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Products under Investigation by Universities/Institutes 28
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development 29
Abivax SA 29
AnGes MG Inc 30
ANP Technologies Inc 31
Arno Therapeutics Inc 32
BioCryst Pharmaceuticals Inc 33
BioFactura Inc 34
Celgene Corp 35
Emergent BioSolutions Inc 36
Enyo Pharma SAS 37
Etubics Corp 38
GeoVax Labs Inc 39
Gilead Sciences Inc 40
GlaxoSmithKline Plc 41
Hemispherx Biopharma Inc 42
Humabs BioMed SA 43
Immune Response BioPharma Inc 44
Immunovaccine Inc 45
Inovio Pharmaceuticals Inc 46
Integrated BioTherapeutics Inc 47
Johnson & Johnson 48
Kineta Inc 49
Kymab Ltd 50
Medicago Inc 51
Merck & Co Inc 52
Microbiotix Inc 53
Micropharm Ltd 54
NanoViricides Inc 55
Navigen Pharmaceuticals, Inc. 56
Novavax Inc 57
Peregrine Pharmaceuticals Inc 58
Phelix Therapeutics LLC 59
PlantForm Corp 60
Profectus BioSciences Inc 61
RedHill Biopharma Ltd 62
Regeneron Pharmaceuticals Inc 63
Rodos BioTarget GmbH 64
SignPath Pharma Inc 65
Sirnaomics Inc 66
Soligenix Inc 67
Taiga Biotechnologies Inc 68
Tamir Biotechnology Inc 69
TGV-Laboratories 70
Toyama Chemical Co Ltd 71
Vaxart Inc 72
XBiotech Inc 73
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Combination Products 75
Assessment by Target 76
Assessment by Mechanism of Action 78
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
(Ebola + Marburg) (monovalent) vaccine - Drug Profile 84
(Ebola + Marburg) (trivalent) vaccine - Drug Profile 86
(Ebola + Marburg) vaccine - Drug Profile 88
(Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile 89
(Ebola [Sudan] + Marburg) vaccine - Drug Profile 93
(Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile 94
(REGN-3470 + REGN-3471 + REGN-3479) - Drug Profile 95
1-E703 - Drug Profile 96
ABX-544 - Drug Profile 97
ANP-015 - Drug Profile 98
Antibodies for Ebola and Marburg Viral Infections - Drug Profile 99
Antibody for Ebola Viral Infection - Drug Profile 100
AR-12 - Drug Profile 101
ARD-5 - Drug Profile 104
bavituximab - Drug Profile 105
CC-11050 - Drug Profile 120
cosfroviximab + larcaviximab + porgaviximab - Drug Profile 121
DEF-201 - Drug Profile 124
DLANA-14 - Drug Profile 126
DPX-Ebola - Drug Profile 127
Drug for Ebola Virus Infection - Drug Profile 128
Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile 129
Ebola (virus like particle) vaccine - Drug Profile 130
Ebola [Zaire] (monovalent) vaccine - Drug Profile 131
Ebola [Zaire] vaccine - Drug Profile 133
Ebola [Zaire] vaccine - Drug Profile 138
Ebola [Zaire] vaccine - Drug Profile 139
Ebola [Zaire] vaccine - Drug Profile 140
Ebola [Zaire] vaccine - Drug Profile 142
Ebola [Zaire] vaccine - Drug Profile 144
Ebola [Zaire] vaccine - Drug Profile 145
Ebola vaccine - Drug Profile 146
Ebola vaccine - Drug Profile 147
Ebola vaccine - Drug Profile 148
Ebola vaccine - Drug Profile 149
Ebola vaccine - Drug Profile 150
Ebola vaccine - Drug Profile 151
Ebola vaccine - Drug Profile 152
EBOTAb - Drug Profile 153
favipiravir - Drug Profile 154
FBH-004 - Drug Profile 157
FDX-000 - Drug Profile 158
Fibrinoplate-S - Drug Profile 159
galidesivir - Drug Profile 160
Gene Therapy for Ebola Virus Infections - Drug Profile 163
GOVXE-301 - Drug Profile 164
GOVXE-302 - Drug Profile 165
GreEMTri - Drug Profile 166
GS-5734 - Drug Profile 167
imatinib mesylate - Drug Profile 168
ImmunoRx - Drug Profile 169
INO-4212 - Drug Profile 170
interferon alfa-n3 - Drug Profile 172
IRE-101 - Drug Profile 176
KIN-1400 - Drug Profile 177
KV-7005 - Drug Profile 179
Lalistat - Drug Profile 180
Lipocurc - Drug Profile 181
mAb-100 - Drug Profile 183
mAb-114 - Drug Profile 184
MB-003 - Drug Profile 185
MBX-2806 - Drug Profile 186
MIL-77 - Drug Profile 187
Monoclonal Antibodies 1 for Ebolavirus Infections - Drug Profile 188
Monoclonal Antibodies 2 for Ebolavirus Infections - Drug Profile 189
Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 190
Monoclonal Antibodies for Ebola Viral Infections - Drug Profile 191
Monoclonal Antibodies for Viral Infections - Drug Profile 192
Monoclonal Antibodies to Inhibit Glycoproteins for Ebola Viral Infections - Drug Profile 193
MonoClonal Antibody for Ebola and Marburg Infections - Drug Profile 194
Monoclonal Antibody for Ebola Viral Infections - Drug Profile 195
Monoclonal Antibody for Ebola Viral Infections - Drug Profile 196
Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile 197
MV-4 - Drug Profile 198
NCK-8 - Drug Profile 199
nilotinib - Drug Profile 200
OS-2966 - Drug Profile 201
ranpirnase - Drug Profile 203
RBT-05 - Drug Profile 206
Recombinant Protein VSF for Viral Infections - Drug Profile 207
rintatolimod - Drug Profile 208
RKP-00156 - Drug Profile 217
SAB-139 - Drug Profile 218
Small Molecule 1 for Ebola Viral Infection - Drug Profile 219
Small Molecule 2 for Ebola Viral Infection - Drug Profile 220
Small Molecule for Ebola Viral Infection - Drug Profile 221
Small Molecules for Ebola and Marburg Infections - Drug Profile 222
Small Molecules for Ebola and Marburg Infections - Drug Profile 223
Small Molecules for Ebola and Marburg Virus Infections - Drug Profile 224
Small Molecules for Ebola Viral Infections - Drug Profile 225
Small Molecules for Ebola Virus Infections - Drug Profile 226
Small Molecules for Ebolavirus Infections - Drug Profile 227
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 228
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 229
Small Molecules to Inhibit NPC1 for Ebola Viral Infections - Drug Profile 230
Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections - Drug Profile 231
Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile 232
STP-802 - Drug Profile 233
Synthetic Peptides for Ebola Virus - Drug Profile 234
TMR-004 - Drug Profile 235
UV-4B - Drug Profile 236
V-920 - Drug Profile 237
ZMAb - Drug Profile 242
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects 243
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products 248
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones 249
Featured News & Press Releases 249
Appendix 265
Methodology 265
Coverage 265
Secondary Research 265
Primary Research 265
Expert Panel Validation 265
Contact Us 265
Disclaimer 266

List of Tables

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2016 19
Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Development, H2 2016 28
Comparative Analysis by Unknown Stage Development, H2 2016 29
Products under Development by Companies, H2 2016 30
Products under Development by Companies, H2 2016 (Contd..1) 31
Products under Development by Companies, H2 2016 (Contd..2) 32
Products under Development by Companies, H2 2016 (Contd..3) 33
Products under Development by Companies, H2 2016 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abivax SA, H2 2016 36
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AnGes MG Inc, H2 2016 37
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2016 38
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Arno Therapeutics Inc, H2 2016 39
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2016 40
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioFactura Inc, H2 2016 41
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Celgene Corp, H2 2016 42
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2016 43
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Enyo Pharma SAS, H2 2016 44
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2016 45
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2016 46
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Gilead Sciences Inc, H2 2016 47
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by GlaxoSmithKline Plc, H2 2016 48
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Hemispherx Biopharma Inc, H2 2016 49
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Humabs BioMed SA, H2 2016 50
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Immune Response BioPharma Inc, H2 2016 51
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Immunovaccine Inc, H2 2016 52
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 53
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, H2 2016 54
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Johnson & Johnson, H2 2016 55
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2016 56
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Kymab Ltd, H2 2016 57
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Medicago Inc, H2 2016 58
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Merck & Co Inc, H2 2016 59
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Microbiotix Inc, H2 2016 60
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Micropharm Ltd, H2 2016 61
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by NanoViricides Inc, H2 2016 62
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 63
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Novavax Inc, H2 2016 64
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 65
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Phelix Therapeutics LLC, H2 2016 66
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by PlantForm Corp, H2 2016 67
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2016 68
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by RedHill Biopharma Ltd, H2 2016 69
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 70
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, H2 2016 71
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by SignPath Pharma Inc, H2 2016 72
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Sirnaomics Inc, H2 2016 73
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Soligenix Inc, H2 2016 74
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Taiga Biotechnologies Inc, H2 2016 75
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Tamir Biotechnology Inc, H2 2016 76
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by TGV-Laboratories, H2 2016 77
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Toyama Chemical Co Ltd, H2 2016 78
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Vaxart Inc, H2 2016 79
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by XBiotech Inc, H2 2016 80
Assessment by Monotherapy Products, H2 2016 81
Assessment by Combination Products, H2 2016 82
Number of Products by Stage and Target, H2 2016 84
Number of Products by Stage and Mechanism of Action, H2 2016 86
Number of Products by Stage and Route of Administration, H2 2016 88
Number of Products by Stage and Molecule Type, H2 2016 90
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H2 2016 250
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects (Contd..1), H2 2016 251
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects (Contd..2), H2 2016 252
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects (Contd..3), H2 2016 253
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects (Contd..4), H2 2016 254
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products, H2 2016 255